Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
36
Participants
Timeline
Start Date
August 31, 2023
Primary Completion Date
October 31, 2026
Study Completion Date
February 28, 2027
Conditions
CancerCancer of PancreasSarcomaHepatic MetastasisSolid Tumor
Interventions
DRUG
STI-1386
Second generation oncolytic virus
All Listed Sponsors
lead
Sorrento Therapeutics, Inc.
INDUSTRY
NCT05361954 - Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter